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Conclusions: This meta-analysis shows a modest but signiﬁcant 
improvement in overall survival and local failures at the expense of a 
clearly increased severe esophagitis. Difﬁculties of increased treat-
ment frequency and the continuous therapy over weekends make these 
strategies hard to adopt. On the other hand, due to the heterogeneity of 
altered fractionation modalities among the trials included, our results 
should be considered with caution and must be interpreted as an hy-
pothesis generator.
TRIAL n HFRT type Chemotherapy Median OS p
Ball 204 60 Gy in 3 wks Weekly CBDCA 14.7 vs 15.4 ns
Saunders 
(CHART) 563
54 Gy in  
12 consecutive days No CT 16.5 vs 13 0.008
Bonner 99 60 Gy in 4 wks split CDDP-VP16 11.6 vs 8.6 ns
ECOG 2597 112 57.6 Gy in  13 consecutive days
CBDCA-paclitaxel 
before RT 20.3 vs 14.9 ns
RTOG 8808 458 69.6 Gy in 6 wks CDDP-VBL 12 vs 11.4 ns
Schild 234 60 Gy in 4 wks split CDDP-VP16 14 vs 15 ns
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Background: A commonly used prognostic classiﬁcation for brain 
metastasis patients is the Recursive Partitioning Analysis (RPA) clas-
siﬁcation developed with data from patients enrolled in RTOG trials 
from 1979 to 1993, which includes performance status, age, presence 
of extracranial metastasis and control of primary disease. The purpose 
of the current study was to determine if additional variables are signiﬁ-
cant independent predictors of survival in NSCLC patients with brain 
metastases.
Methods: In protocol 9801, 401 pts with brain metastases from any 
primary tumor were randomized to whole brain radiation therapy 
(WBRT, 30 Gy/10 fractions) or WBRT+MGd, 5 mg/kg qd x 10 days. 
The subgroup of 251 pts with NSCLC is included in this analysis. 
In protocol 0211, 554 pts with brain metastases from NSCLC were 
randomized to the same treatments. In both studies, eligibility included 
a KPS≥70, no liver metastases, and ≤1 site of extracranial metastasis. 
Univariate and stepwise multivariate Cox analyses were carried out 
using baseline clinical variables, laboratory values, neurocognitive test 
scores and survival follow-up data. Hazard ratios (HR) less than 1 favor 
the speciﬁed group.
Results: 805 patients, with a median age of 59 years, 44.6% female, 
55.4% male, 53.3% adenocarcinoma, 19.3% NSCLC, not otherwise 
speciﬁed (NOS), 13.4% squamous cell, 10.6% large cell, 0.9% bron-
choalveolar, 19.7% single brain metastasis, 80.3% multiple brain me-
tastases, 47% extracranial metastases, and 84% presentation with neu-
rologic deﬁcits were randomized to WBRT (N=403) or WBRT+MGd 
(N=402). Time to neurologic progression in the WBRT+MGd group 
was 15.4 months, signiﬁcantly longer than the 9.0 months for the 
WBRT alone group, p=0.016, HR=0.74 (95% CI 0.57-0.95). Median 
survival overall was 5.5 months, without statistically signiﬁcant differ-
ence between treatment groups. Univariate predictors of survival were 
age, performance status, sex, histology, geographic region, low LDH, 
high LDH, low albumin, low Hgb, impaired memory (HVLT recall 
and recognition tests), verbal ﬂuency (COWA test), executive function 
(Trailmaking test B), number of impaired neurocognitive tests, and 
smoking history. RPA class was borderline predictive in a univariate 
model (HR=1.27, P=0.056 for RPA class II vs I). In a stepwise model 
of all variables, age ≥65 (HR=1.34, P=0.005), KPS 90-100 (HR=0.70, 
P<0.001), multiple brain metastases (HR=1.27, P=0.035), presence 
of extracranial metastases (HR=1.21, P=0.036), male sex (HR=1.34, 
P=0.001), non-small-cell histology (NOS) (HR=1.37, P=0.005), 
Canada (HR=1.28, P=0.013), high baseline LDH (HR=1.39, P=0.023), 
low baseline LDH (HR=0.49, P=0.046), low baseline albumin (HR 
1.64, P<0.001), current smoker (HR=1.29, P=0.009) were independent 
predictors of survival. 
Conclusions: In two large randomized trials of patients with NSCLC 
and brain metastases, older age, poorer performance status, multiple 
brain metastases, presence of extracranial metastases, male sex, 
elevated LDH and albumin, current smoking status, and residence in 
Canada were signiﬁcant predictors of shorter survival. These variables 
may provide more predictive power than RPA class for future random-
ized trials in NSCLC patients with brain metastases that have survival 
as an endpoint.
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Objectives: The extend of lymph node involvement in patients with 
non-small cell lung cancer (NSCLC) is the most important prognostic 
factor and inﬂuences multimodality treatment. We studied safety, ac-
curacy and characteristics of intraoperative ultrasound (US) guided sys-
tematic mediastinal nodal dissection in patients with resected NSCLC.
Methods: Intraoperative hand held ultrasound probe was used in sys-
tematic mediastinal nodal dissection in 54 patients after radical surgery 
for NSCLC. Mapping of the lymph nodes by their number and station 
followed by histopathologic evaluation was performed. Data were com-
pared with 58 patients who underwent lung resections and systematic 
mediastinal nodal dissection for NSCLC within the same time period at 
our institution. Statistical analysis was carried out.
Results: The surgical procedure used depended on the extent of the 
disease, as well as the cardiopulmonary reserve of the patients and was 
comparable in both groups. Operating time was prolonged for 12 (6 
- 20) minutes in patients with US guided mediastinal nodal dissection, 
but number and stations of evaluated lymph nodes was signiﬁcantly 
higher (p>0.001) at the same group of patients. Skip nodal metastases 
were found in 24% of patients without N1 nodal involvement. Standard 
staging system seemed to be improved in US guided mediastinal 
lymphadenectomy patients. Complications rate showed no difference 
between analyzed groups of patients.
Conclusion: Higher number and location of analyzed mediastinal 
nodal stations in patients with resected NSCLC using hand held ultra-
sound probe suggested to be of great oncology signiﬁcance. Procedure 
